• Population : Immunocompetent children aged 9–24 months
  • Intervention: Single-dose MenA conjugate vaccine (5 µg dosage)
  • Comparison: No MenA vaccination
  • Outcome : Serogroup A meningococcal disease

What is the scientific evidence concerning the efficacy of a single dose of MenA conjugate vaccine (versus no Men A vaccination) against serogroup A meningococcal disease in immunocompetent children aged 9–24 months?

  • GRADE table
  • Meningococcal disease